366 related articles for article (PubMed ID: 30173619)
1. Virus-like particle vaccines: immunology and formulation for clinical translation.
Donaldson B; Lateef Z; Walker GF; Young SL; Ward VK
Expert Rev Vaccines; 2018 Sep; 17(9):833-849. PubMed ID: 30173619
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant formulations for virus-like particle (VLP) based vaccines.
Cimica V; Galarza JM
Clin Immunol; 2017 Oct; 183():99-108. PubMed ID: 28780375
[TBL] [Abstract][Full Text] [Related]
3. The 5th virus-like particle and nano-particle vaccines (VLPNPV) conference.
Engeroff P; Bachmann MF
Expert Rev Vaccines; 2019 Jan; 18(1):1-3. PubMed ID: 30526126
[TBL] [Abstract][Full Text] [Related]
4. Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.
Beljanski V; Chiang C; Kirchenbaum GA; Olagnier D; Bloom CE; Wong T; Haddad EK; Trautmann L; Ross TM; Hiscott J
J Virol; 2015 Oct; 89(20):10612-24. PubMed ID: 26269188
[TBL] [Abstract][Full Text] [Related]
5. Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats.
Hwang HS; Kim KH; Lee Y; Lee YT; Ko EJ; Park S; Lee JS; Lee BC; Kwon YM; Moore ML; Kang SM
Hum Vaccin Immunother; 2017 May; 13(5):1031-1039. PubMed ID: 28129031
[TBL] [Abstract][Full Text] [Related]
6. Plant-derived H7 VLP vaccine elicits protective immune response against H7N9 influenza virus in mice and ferrets.
Pillet S; Racine T; Nfon C; Di Lenardo TZ; Babiuk S; Ward BJ; Kobinger GP; Landry N
Vaccine; 2015 Nov; 33(46):6282-9. PubMed ID: 26432915
[TBL] [Abstract][Full Text] [Related]
7. Rapid Responses to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: A Randomized Controlled Trial.
Atmar RL; Baehner F; Cramer JP; Song E; Borkowski A; Mendelman PM;
J Infect Dis; 2016 Sep; 214(6):845-53. PubMed ID: 27354368
[TBL] [Abstract][Full Text] [Related]
8. IgG and IgM responses to human papillomavirus L1 virus-like particle as a function of dosing schedule and vaccine formulation.
Park MH; You JW; Kim HJ; Kim HJ
J Microbiol; 2019 Sep; 57(9):821-827. PubMed ID: 31452045
[TBL] [Abstract][Full Text] [Related]
9. A Single Intramuscular Dose of a Plant-Made Virus-Like Particle Vaccine Elicits a Balanced Humoral and Cellular Response and Protects Young and Aged Mice from Influenza H1N1 Virus Challenge despite a Modest/Absent Humoral Response.
Hodgins B; Yam KK; Winter K; Pillet S; Landry N; Ward BJ
Clin Vaccine Immunol; 2017 Dec; 24(12):. PubMed ID: 29021303
[TBL] [Abstract][Full Text] [Related]
10. A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity.
Zhang W; Dai W; Zhang C; Zhou Y; Xiong P; Wang S; Ye X; Liu Q; Zhou D; Huang Z
Emerg Microbes Infect; 2018 May; 7(1):94. PubMed ID: 29777102
[TBL] [Abstract][Full Text] [Related]
11. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.
Tumban E; Muttil P; Escobar CA; Peabody J; Wafula D; Peabody DS; Chackerian B
Vaccine; 2015 Jun; 33(29):3346-53. PubMed ID: 26003490
[TBL] [Abstract][Full Text] [Related]
12. Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination.
Mohsen MO; Gomes AC; Cabral-Miranda G; Krueger CC; Leoratti FM; Stein JV; Bachmann MF
J Control Release; 2017 Apr; 251():92-100. PubMed ID: 28257987
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults.
Chichester JA; Green BJ; Jones RM; Shoji Y; Miura K; Long CA; Lee CK; Ockenhouse CF; Morin MJ; Streatfield SJ; Yusibov V
Vaccine; 2018 Sep; 36(39):5865-5871. PubMed ID: 30126674
[TBL] [Abstract][Full Text] [Related]
14. Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display.
Singh SK; Thrane S; Janitzek CM; Nielsen MA; Theander TG; Theisen M; Salanti A; Sander AF
Vaccine; 2017 Jun; 35(30):3726-3732. PubMed ID: 28578824
[TBL] [Abstract][Full Text] [Related]
15. Structural Characterization and Formulation Development of a Trivalent Equine Encephalitis Virus-Like Particle Vaccine Candidate.
Toprani VM; Cheng Y; Wahome N; Khasa H; Kueltzo LA; Schwartz RM; Middaugh CR; Joshi SB; Volkin DB
J Pharm Sci; 2018 Oct; 107(10):2544-2558. PubMed ID: 29883665
[TBL] [Abstract][Full Text] [Related]
16. Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses.
Janitzek CM; Matondo S; Thrane S; Nielsen MA; Kavishe R; Mwakalinga SB; Theander TG; Salanti A; Sander AF
Malar J; 2016 Nov; 15(1):545. PubMed ID: 27825348
[TBL] [Abstract][Full Text] [Related]
17. ISCOMATRIX™ adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with virus neutralization in humans.
Chung KY; Coyle EM; Jani D; King LR; Bhardwaj R; Fries L; Smith G; Glenn G; Golding H; Khurana S
Vaccine; 2015 Jul; 33(32):3953-62. PubMed ID: 26093202
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in mucosal immunization using virus-like particles.
Vacher G; Kaeser MD; Moser C; Gurny R; Borchard G
Mol Pharm; 2013 May; 10(5):1596-609. PubMed ID: 23548071
[TBL] [Abstract][Full Text] [Related]
19. Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles.
Lin YL; Yu CI; Hu YC; Tsai TJ; Kuo YC; Chi WK; Lin AN; Chiang BL
Vaccine; 2012 Feb; 30(7):1305-12. PubMed ID: 22214888
[TBL] [Abstract][Full Text] [Related]
20. Formulation and stabilization of recombinant protein based virus-like particle vaccines.
Jain NK; Sahni N; Kumru OS; Joshi SB; Volkin DB; Russell Middaugh C
Adv Drug Deliv Rev; 2015 Oct; 93():42-55. PubMed ID: 25451136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
